BC Innovations | Apr 17, 2018
Distillery Therapeutics

Ophthalmic disease

INDICATION: Diabetic macular edema (DME) In vitro , mouse and rat studies identified two bicyclic peptide inhibitors of KLKB1 that could help treat DME. Screening of a bicyclic peptide library in KLKB1 binding assays followed by...
BioCentury | Oct 13, 2017
Regulation

Expanding the HAE tool kit

Despite an increasingly crowded market, hereditary angioedema patients who attended FDA’s Patient-Focused Drug Development meeting said there remains room for improvement in dosing convenience and reducing attack frequency. Two subcutaneous prophylactics that have completed Phase...
BC Extra | May 18, 2017
Clinical News

Shire HAE treatment from Dyax deal clears Phase III hurdle

Shire plc (LSE:SHP; NASDAQ:SHPG) said it will submit a BLA to FDA by early next year for subcutaneous lanadelumab (SHP643) to prevent hereditary angioedema attacks. The company will base its submission on data from the...
BioCentury | May 12, 2017
Strategy

Vertical vision

Shire plc ’s deal with Parion Sciences Inc. is a step toward building vertically in ophthalmics, much like it has done in hereditary angioedema and hemophilia. On May 1, Shire gained exclusive, worldwide rights to...
BioCentury | Jan 18, 2016
Strategy

Shire's serial story

The most obvious benefits Shire plc expects to gain by acquiring Baxalta Inc. are a slew of new products and the cash to make subsequent acquisitions the company couldn't have made on its own. But...
BC Week In Review | Nov 9, 2015
Company News

Dyax, Shire deal

Shire will acquire Dyax for $37.30 per share, or $5.9 billion in cash. The price represents a 35% premium to Dyax’s close of $27.53 on Oct. 30, the last trading day before the deal was...
BC Extra | Nov 3, 2015
Top Story

Shire builds on HAE franchise with Dyax takeout

Shire plc (LSE:SHP; NASDAQ:SHPG) will acquire Dyax Corp. (NASDAQ:DYAX) for $37.30 per share, or $5.9 billion in cash. The price represents a 35% premium to Dyax's close of $27.53 on Oct. 30, the last trading...
BioCentury | Oct 5, 2015
Finance

Event planner

For investors who are not inclined to sit it out until the volatility abates, the fourth quarter is bursting with late-stage catalysts. There are no fewer than 17 PDUFA dates on the calendar before year...
BC Extra | Apr 1, 2015
Clinical News

Dyax surges on DX-2930 news

Dyax Corp. (NASDAQ:DYAX) jumped $8.40 (50%) to $25.15 in early after-hours trading on Tuesday on postmarket news that its DX-2930 significantly reduced hereditary angioedema (HAE) attacks in a Phase Ib trial. The company, which also...
BC Week In Review | Apr 14, 2014
Clinical News

Kalbitor ecallantide regulatory update

FDA approved an sBLA from Dyax for Kalbitor ecallantide to treat hereditary angioedema (HAE) attacks to expand the age range to >=12 years from >=16 years. Dyax markets the subcutaneously delivered yeast-derived recombinant plasma kallikrein...
Items per page:
1 - 10 of 248